SLEEP: SLeep Education for Everyone March 4, 2021 - April 15, 2021
Virtual
Each session is designed to last about 30 minutes each.
Each module includes a short 2-3 minute educational video designed to deliver key concepts.
The rest of the time is spent discussing the topics, brainstorming solutions to possible obstacles to improving sleep, and goal setting.
We are very excited to be able to offer this program.
Where: Online Via Zoom
Cost: There is no cost for the workshop. The program is supported financially by Michigan State University Extension. March 16, 2021 – February 15, 2022 virtual - Zoom
This course is designed for people who are at-risk for developin
• The application includes robust data from the Phase 3 registration program, which demonstrated efficacy of daridorexant on objective and subjective sleep parameters, and an improvement in daytime
New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong
First Drug Approval for Dayvigo in Asia Outside of Japan
TOKYO, Mar 2, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. This approval is the first approval for DAYVIGO in Asia outside of Japan.
DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm. DAYVIGO binds to orexin receptors OX1R and OX2R and ac